Literature DB >> 30370081

Neoadjuvant chemoradiotherapy followed by surgery is associated with better survival outcomes in patients with locally advanced esophageal squamous cell carcinoma.

Naoya Yoshida1,2, Hideo Baba2.   

Abstract

Entities:  

Year:  2018        PMID： 30370081      PMCID： PMC6186577          DOI： 10.21037/jtd.2018.08.78

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  10 in total

1.  Preoperative chemoradiotherapy for esophageal or junctional cancer.

Authors:  P van Hagen; M C C M Hulshof; J J B van Lanschot; E W Steyerberg; M I van Berge Henegouwen; B P L Wijnhoven; D J Richel; G A P Nieuwenhuijzen; G A P Hospers; J J Bonenkamp; M A Cuesta; R J B Blaisse; O R C Busch; F J W ten Kate; G-J Creemers; C J A Punt; J T M Plukker; H M W Verheul; E J Spillenaar Bilgen; H van Dekken; M J C van der Sangen; T Rozema; K Biermann; J C Beukema; A H M Piet; C M van Rij; J G Reinders; H W Tilanus; A van der Gaast
Journal:  N Engl J Med       Date:  2012-05-31       Impact factor: 91.245

2.  Guidelines for Diagnosis and Treatment of Carcinoma of the Esophagus April 2012 edited by the Japan Esophageal Society.

Authors:  Hiroyuki Kuwano; Yasumasa Nishimura; Tsuneo Oyama; Hiroyuki Kato; Yuko Kitagawa; Motoyasu Kusano; Hideo Shimada; Hiroya Takiuchi; Yasushi Toh; Yuichiro Doki; Yoshio Naomoto; Hisahiro Matsubara; Tatsuya Miyazaki; Manabu Muto; Akio Yanagisawa
Journal:  Esophagus       Date:  2014-11-11       Impact factor: 4.230

3.  Definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in advanced esophageal cancer: a phase 2 trial (KDOG 0501-P2).

Authors:  Katsuhiko Higuchi; Shouko Komori; Satoshi Tanabe; Chikatoshi Katada; Mizutomo Azuma; Hiromichi Ishiyama; Tohru Sasaki; Kenji Ishido; Natsuya Katada; Kazushige Hayakawa; Wasaburo Koizumi
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-05-24       Impact factor: 7.038

4.  Preoperative prediction of a pathologic complete response of esophageal squamous cell carcinoma to neoadjuvant chemoradiotherapy.

Authors:  Yoichi Hamai; Jun Hihara; Manabu Emi; Takaoki Furukawa; Yuji Murakami; Ikuno Nishibuchi; Yasushi Nagata; Yuta Ibuki; Ichiko Yamakita; Tomoaki Kurokawa; Morihito Okada
Journal:  Surgery       Date:  2018-03-05       Impact factor: 3.982

5.  Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study.

Authors:  Maxime J M van der Valk; Denise E Hilling; Esther Bastiaannet; Elma Meershoek-Klein Kranenbarg; Geerard L Beets; Nuno L Figueiredo; Angelita Habr-Gama; Rodrigo O Perez; Andrew G Renehan; Cornelis J H van de Velde
Journal:  Lancet       Date:  2018-06-23       Impact factor: 79.321

6.  Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906).

Authors:  Ken Kato; Kei Muro; Keiko Minashi; Atsushi Ohtsu; Satoshi Ishikura; Narikazu Boku; Hiroya Takiuchi; Yoshito Komatsu; Yoshinori Miyata; Haruhiko Fukuda
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-10-06       Impact factor: 7.038

7.  Value and application of trimodality therapy or definitive concurrent chemoradiotherapy in thoracic esophageal squamous cell carcinoma.

Authors:  Wei-Cheng Lin; Yi-Fang Ding; Han-Lin Hsu; Jer-Hwa Chang; Kevin Sheng-Po Yuan; Alexander T H Wu; Jyh-Ming Chow; Chia-Lun Chang; Shee-Uan Chen; Szu-Yuan Wu
Journal:  Cancer       Date:  2017-06-13       Impact factor: 6.860

8.  Phase I/II study of docetaxel, cisplatin, and 5-fluorouracil combination chemoradiotherapy in patients with advanced esophageal cancer.

Authors:  Tatsuya Miyazaki; Makoto Sohda; Naritaka Tanaka; Shigemasa Suzuki; Keisuke Ieta; Makoto Sakai; Akihiko Sano; Takehiko Yokobori; Takanori Inose; Masanobu Nakajima; Minoru Fukuchi; Hitoshi Ojima; Hiroyuki Kato; Hiroyuki Kuwano
Journal:  Cancer Chemother Pharmacol       Date:  2014-12-28       Impact factor: 3.333

9.  TNM Staging Matched-pair Comparison of Surgery After Neoadjuvant Chemoradiotherapy, Surgery Alone and Definitive Chemoradiotherapy for Thoracic Esophageal Squamous Cell Carcinoma.

Authors:  ShiLiang Liu; Bo Qiu; GuangYu Luo; Ying Liang; YuZhen Zheng; ZhaoLin Chen; KongJia Luo; Mian Xi; Qing Liu; YongHong Hu; Qun Li; JianHua Fu; MengZhong Liu; Hong Yang; Hui Liu
Journal:  J Cancer       Date:  2017-02-25       Impact factor: 4.207

10.  Neoadjuvant vs definitive concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma patients.

Authors:  Chih-Yi Chen; Chia-Chin Li; Chun-Ru Chien
Journal:  World J Surg Oncol       Date:  2018-07-14       Impact factor: 2.754
  10 in total
  1 in total

1.  Pathological complete response after neoadjuvant treatment determines survival in esophageal squamous cell carcinoma patients (NEOCRTEC5010).

Authors:  Jianfei Shen; Min Kong; Hong Yang; Ke Jin; Yuping Chen; Wentao Fang; Baofu Chen; Chengchu Zhu; Zhentao Yu; Weimin Mao; Jiaqing Xiang; Yongtao Han; Zhijian Chen; Haihua Yang; Jiaming Wang; Qingsong Pang; Xiao Zheng; Huanjun Yang; Tao Li; Xu Zhang; Qun Li; Geng Wang; Teng Mao; Xufeng Guo; Ting Lin; Mengzhong Liu; Dehua Ma; Minhua Ye; Chunguo Wang; Zheng Wang; Alessandro Brunelli; Robert J Cerfolio; Xavier Benoit D'Journo; Hiran C Fernando; Florian Lordick; Jianhua Fu
Journal:  Ann Transl Med       Date:  2021-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.